ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

lenvatinib

Also written as “Lenvatinib”, “E7080” and “HOPE”.

Its studies are mostly in Carcinoma, Hepatocellular · Melanoma · Thyroid Neoplasms · Carcinoma, Non-Small-Cell Lung · Carcinoma, Renal Cell, led by 4 companies.

Drug pageLenvatinib: every studyAll 431 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jun 19, 201879 company-led studies, 3 open or runningNext primary completion: Oct 22, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eisaiits history only511 open or runningphase 4since Jun 19, 2018Jul 15, 2005none ahead
Merckits history only261 open or runningphase 3since Jan 22, 2019Aug 3, 2016Oct 22, 2027phase 2 · NCT02861573
AGO Researchits history only11 open or runningphase 2since May 11, 2023May 11, 2023Oct 30, 2027phase 2 · NCT05903833
Merck KGaA, Darmstadt, Germany10 open or runningphase 1since Oct 4, 2021Oct 4, 2021none ahead

Also a collaborator on its studies: Ono Pharmaceutical, PharmaBio Development and Quintiles.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Merck KGaA, Darmstadt, Germany only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 4, 2021First study: phase 1 study in Central Nervous System NeoplasmsFirst studyNCT05081180 · 17 enrolled · Canada, France, Germany and more

TargetBeta

“A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase ”NCIt, by rule
“Vascular endothelial growth factor receptor inhibitor”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
nintedanibruleBoehringer Ingelheimphase 476
regorafenibruleBayerphase 440
AxitinibrulePfizerphase 345
chiauranibruleChipscreen Biosciencesphase 315

Studies

The one study Merck KGaA, Darmstadt, Germany leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05081180Central Nervous System Neoplasms · Canada, France, Germany and more1TerminatedFeb 11, 202617

How it is read

Names in the registry

  • “Lenvatinib”, 72 entries
  • “lenvatinib”, 7 entries
  • “E7080”, 6 entries
  • “HOPE”, 2 entries
  • “E7080 capsule”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.